Skip to main content

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Publication ,  Journal Article
Kumar, S; Kaufman, JL; Gasparetto, C; Mikhael, J; Vij, R; Pegourie, B; Benboubker, L; Facon, T; Amiot, M; Moreau, P; Punnoose, EA; Alzate, S ...
Published in: Blood
November 2017

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. In this phase 1 study, patients with relapsed/refractory MM received venetoclax monotherapy. After a 2-week lead-in with weekly dose escalation, daily venetoclax was given at 300, 600, 900, or 1200 mg in dose-escalation cohorts and 1200 mg in the safety expansion. Dexamethasone could be added on progression during treatment. Sixty-six patients were enrolled (30, dose-escalation cohorts; 36, safety expansion). Patients received a median of 5 prior therapies (range, 1-15); 61% were bortezomib and lenalidomide double refractory, and 46% had t(11;14). Venetoclax was generally well tolerated. Most common adverse events included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]). Cytopenias were the most common grade 3/4 events, with thrombocytopenia (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported. The overall response rate (ORR) was 21% (14/66), and 15% achieved very good partial response or better (≥VGPR). Most responses (12/14 [86%]) were reported in patients with t(11;14). In this group, ORR was 40%, with 27% of patients achieving ≥VGPR. Biomarker analysis confirmed that response to venetoclax correlated with higher BCL2:BCL2L1 and BCL2:MCL1 mRNA expression ratios. Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t(11;14) abnormality and those with a favorable BCL2 family profile. Registered at www.clinicaltrials.gov: #NCT01794520.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 2017

Volume

130

Issue

22

Start / End Page

2401 / 2409

Related Subject Headings

  • Sulfonamides
  • Neoplasm Recurrence, Local
  • Multiple Myeloma
  • Molecular Targeted Therapy
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Female
  • Bridged Bicyclo Compounds, Heterocyclic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., … Touzeau, C. (2017). Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 130(22), 2401–2409. https://doi.org/10.1182/blood-2017-06-788786
Kumar, Shaji, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, et al. “Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.Blood 130, no. 22 (November 2017): 2401–9. https://doi.org/10.1182/blood-2017-06-788786.
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov;130(22):2401–9.
Kumar, Shaji, et al. “Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.Blood, vol. 130, no. 22, Nov. 2017, pp. 2401–09. Epmc, doi:10.1182/blood-2017-06-788786.
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov;130(22):2401–2409.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 2017

Volume

130

Issue

22

Start / End Page

2401 / 2409

Related Subject Headings

  • Sulfonamides
  • Neoplasm Recurrence, Local
  • Multiple Myeloma
  • Molecular Targeted Therapy
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Female
  • Bridged Bicyclo Compounds, Heterocyclic